I wrote:
Thank you for this article (and please excuse a British person’s lack of Norwegian!). It is vital for patients that more biomedical research is carried out into this devastating disease.
I hope that your readers will donate to one of the biomedical charities, such as ME Forskning in Norway (http://me-forskning.no/), who have supported this important work at Haukeland, or Invest in ME, who are fundraising for a UK rituximab trial and B-cell research (www.ukrituximabtrial.org).
The work of the Norwegian researchers indicates that this is now a treatable – even curable – disease. It affects over 25,000 Norwegians and over 17 million people worldwide.
This is a solvable problem but scientists need money to keep working. Many projects are ready to start as soon as they have the funds.
It is impossible to overstate the international importance of this Norwegian research. The use of rituximab and looking at autoimmunity is a huge breakthrough for ME. Norway is leading the rest of the world.
I hope that your readers will donate to one of the biomedical charities, such as ME Forskning in Norway (http://me-forskning.no/), who have supported this important work at Haukeland, or Invest in ME, who are fundraising for a UK rituximab trial and B-cell research (www.ukrituximabtrial.org).
The work of the Norwegian researchers indicates that this is now a treatable – even curable – disease. It affects over 25,000 Norwegians and over 17 million people worldwide.
This is a solvable problem but scientists need money to keep working. Many projects are ready to start as soon as they have the funds.
It is impossible to overstate the international importance of this Norwegian research. The use of rituximab and looking at autoimmunity is a huge breakthrough for ME. Norway is leading the rest of the world.